DARPA Antibody Technology Program: Standardized Test Bed for Antibody Characterization: Characterization of an MS2 ScFv Antibody Produced by Stablebody Technologies
Abstract
The selection of antibodies for inclusion in a final assay format has primarily relied on antibody performance in enzyme-linked immunosorbent assays (ELISAs), with little regard for quantification of the full spectrum of variables affecting antibody-antigen interactions. The Joint Product Management Office for Biosurveillance (JPMO BSV) Defense Biological Product Assurance Office (formerly the Critical Reagents Program) has instituted a quality program for test method standardization to support more comprehensive characterization and comparison of the physical and functional properties of antibody reagents within its repository. Development and standardization of antibody testing provides JPMO BSV with an invaluable platform for the provision of consistent, high-quality assays and reagents for current biodetection platforms as well as the development and validation of future systems. This platform will be used to characterize and evaluate the MS2 recombinant antibody produced and supplied by the Defense Advanced Research Project Agency-funded investigator, Stablebody Technologies, LLC (Madison, WI) for affinity and stability enhancements. The study provides standardized parametric data on antibody properties and performance and contributes to the development of a decisional analysis tool for use in expanding the confidence level for selection of antibody-based reagents that will optimize field operational and performance metrics for future detection and diagnostic platforms.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2018
- Accession Number
- AD1056465
Entities
People
- Alena Calm
- Candice Warner
- Heather Welsh
- James Carney
- Melody Zacharko
- Patricia E. Buckley
- Roy Thompson
Organizations
- Edgewood Chemical Biological Center